Skip to main content
. 2022 Jun 24;62(7):1365–1376. doi: 10.1111/trf.16987

FIGURE 3.

FIGURE 3

The relative risk of TEAMV for recipients of PRPC compared with conventional PC. Risk of TEAMV was reduced for recipients of PRPC <65 years of age, male sex, non‐white race, primary therapy with chemotherapy without HCT, history of pulmonary disease, and history of cardiac disease. p‐values were based on the Breslow–day test for homogeneous odds ratios across subgroups [Color figure can be viewed at wileyonlinelibrary.com]